美国妇产科医师协会DVT和PE预防指南.pdfVIP

NGC banner Guideline Summary NGC-5947 Guideline Title Prevention of deep vein thrombosis and pulmonary embolism. Bibliographic Source(s) American College of Obstetricians and Gynecologists (ACOG). Prevention of deep vein thrombosis and pulmonary embolism. Washington (DC): American College of Obstetricians and Gynecologists (ACOG); 2007 Aug. 12 p. (ACOG  practice bulletin; no. 84). [75 references] Guideline Status This is the current release of the guideline. This guideline updates a previous version: American College of Obstetricians and Gynecologists (ACOG). Prevention of deep vein thrombosis and pulmonary embolism. Washington (DC): American College of Obstetricians and Gynecologists (ACOG); 2000 Oct. 10 p. (ACOG practice bulletin; no. 21). FDA Warning/Regulatory Alert Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released. l   April 7, 2010 – Heparin  : Laboratory studies performed at the request of the U.S. Food and Drug Administration (FDA) have shown that Heparin Sodium, USP (heparin) made under the new United States Pharmacopeia (USP) Monograph (new heparin) has approximately 10% less blood-thinning (anticoagulant) activity compared to heparin prepared using the previous (old) USP Monograph. The studies were performed in order to better understand the clinical impact of the change in potency for heparin. The results of these studies reinforce FDAs previous recommendation for healthcare professionals to exercise clinical judgment in determining the dose of heparin for a patient and consider the clinical circumstances where the potency decrease may require dosage adjustments and more frequent monitoring . Scope Disease/Condition(s) Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE) Guideline Category